A case of squamous cell carcinoma of the head and neck producing granulocyte-colony stimulating factor with marked leukocytosis
A case of squamous cell carcinoma of the head and neck producing granulocyte-colony stimulating factor with marked leukocytosis
复制标题
DOI：
10.1016/j.anl.2006.07.014
复制
发表时间：
2007-06-01
影响因子：
1.7
通讯作者：
Furuya, Nobuhiko
中科院分区：
文献类型：
--
作者：
Toyoda, Minoru;Chikamatsu, Kazuaki;Furuya, Nobuhiko
在头颈部鳞状细胞癌（SCCHN）中，肿瘤细胞分泌可检测到的各种细胞因子，如白细胞介素(IL)-6、IL-10和转化生长因子(TGF)- β。这些肿瘤来源的因素可能是促进恶性肿瘤的原因。在这里，我们描述了一个SCCHN患者肿瘤产生的G-CSF和特点是明显的白细胞增多。在这个45岁的男性患者中，严重的白细胞增多与侵袭性肿瘤生长同时发生。免疫组化（IHC）证实肿瘤产生G-CSF。血清G-CSF水平升高。放疗后白细胞计数和血G-CSF水平下降。肿瘤细胞G-CSF受体阳性，提示G-CSF对自分泌生长有调节作用。此外，我们还用抗p53、抗p -糖蛋白（P-gp）、抗胸腺苷酸合成酶（TS）和抗二氢嘧啶脱氢酶（DPD）对肿瘤细胞进行了免疫组化研究，这些分子被认为有助于获得治疗耐药性。肿瘤细胞TS和DPD染色阳性，p53和P-gp染色阳性。这些结果表明，多种分子可能负责高恶性肿瘤的获得。2006爱思唯尔爱尔兰有限公司版权所有。
In squamous cell carcinoma of the head and neck (SCCHN), tumor cells have been shown to secrete detectable amounts of various cytokines, such as interleukin (IL)-6, IL-10, and transforming growth factor (TGF)-beta. These tumor-derived factors might be responsible for promoting malignancy. Here, we describe a SCCHN patient with tumor produced G-CSF and characterized by marked leukocytosis. In this 45-year-old man, severe leukocytosis developed in parallel with aggressive tumor growth. G-CSF production by the tumor was confirmed by immunohistochemistry (IHC). Serum G-CSF levels were elevated. The leukocyte counts and the blood G-CSF level decreased following a course of radiotherapy. Tumor cells were also positive for G-CSF receptor, suggesting autocrine growth regulation by G-CSF. Moreover, the tumor cells were also investigated by IHC with anti-p53, anti-P-glycoprotein (P-gp), anti-thymidylate synthase (TS), and anti -dihydropyrimidine dehydrogenase (DPD), which molecules are thought to contribute the acquisition of therapeutic resistance. The tumor cells were positively stained for TS and DPD, but neither p53 nor P-gp. These results suggest that a variety of molecules may be responsible for acquisition of high malignancy. (c) 2006 Elsevier Ireland Ltd. All rights reserved.